Feb. 14, 2023
Greg Bowman, a University of Pennsylvania biophysicist, had the kind of idea biotech venture capitalists salivate over. His lab had been working on how to drug “cryptic sites” on proteins that were previously thought unreachable by drug molecules. Machine learning, he believed, would make new types of medicine possible. The idea seemed ready to be spun out of his lab and into a company.
But when Bowman hooked up with a young entrepreneur, Anuj Sharma, to create a new company, Decrypt, they didn’t choose one of the big venture firms to partner with. Instead, they went with an unknown outfit called Curie.Bio. The reason: The terms of the deal were simply much better. Most venture firms would have either required that Bowman and Sharma give up control of their company at an early stage in exchange for taking a hands-on role or would have simply given them money without any help.
“There was a spectrum, from places where we would have basically been advisers to their startup to places that would give us a check and wish us well,” Bowman said. Neither of those options appealed to them.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
